After facing multiple cancers and hospice care, April Floyd credits her service dog Onyx with helping her find comfort, strength and hope.
|Articles|June 17, 2016
Dr. Michael Pearl Discusses Palliative Care
Advertisement
Dr. Michael Pearl breaks down the differences between palliative care and hospice care and explains the New York Palliative Care Information Act in this recording of his recent webinar, “Palliative Care for Women with Cancer.” Dr. Pearl is Professor and Director of the Division of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Reproductive Medicine at Stony Brook University Hospital. Watch it below.
Advertisement
Related to this article
Updated NCCN guidelines for multiple myeloma add dedicated recommendations for MRD testing, prefer tests that can detect one cancer cell among 1 million cells and expand when testing should occur.
Irene Flores' advocacy for bedside nurses helped build a local stem cell transplant program, making her an Extraordinary Healer Award nominee.
Lunsumio added to Revlimid kept relapsed or refractory follicular lymphoma from worsening longer than Rituxan plus Revlimid in the phase 3 CELESTIMO trial.
Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.
See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
Phase 2 findings on divesiran point to a potential way to control hematocrit while reducing repeated blood draws for those living with polycythemia vera, like Nona Baker.
Four of seven patients had no visible cancer on scans in early data from CONVERGE, a trial testing a tumor injection meant to boost radiation in lung cancer.
Advertisement
Advertisement
Trending on CURE
1
Blood Cancer Treatments in the FDA Pipeline: What Could Come Next
2
3 More Lung Cancer Breakthroughs From WCLC 2026
3
FDA Approves Inluriyo Plus Verzenio for Certain Advanced Breast Cancers
4
5 Years of Leukemia Advances: A Timeline of FDA Approvals and What They Mean for Patients
5